On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing application for Calquence (acalabrutinib) for adult patients with previously ...
A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug ...
AstraZeneca’s (AZN) supplemental biologics license application, or sBLA, for Imfinzi has been accepted and granted priority review in the U.S. for the treatment of patients with muscle-invasive ...
FDA grants Priority Review to AstraZeneca’s Imfinzi sBLA for muscle-invasive bladder cancer, with decision expected in Q2 2025. Imfinzi regimen showed a 32% reduced risk of disease progression and a ...
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced on Wednesday that the FDA has accepted a marketing application for their blockbuster antibody drug conjugate, Enhertu, to expand the ...
AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. The drugmaker successfully defended itself against claims senior staff ignored requests to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results